XLifeSc, also known as Xiangxue Life Sciences, specializes in developing TCR-based therapies for cancer. The company has successfully advanced two main proprietary technological platforms to the clinic-ready stage: the High Affinity T Cell Activation Core (HATac) and the TCR Affinity Enhancing Specific T Cell Therapy (TAEST). This has led to the creation of an extensive intellectual property portfolio covering various TCR-related technologies, such as the identification of tumor-specific antigens, antigen-specific TCRs, and the optimization of antigen-specific TCRs.